Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

ARGX

ARGENX SE

Tremor tracks 8 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

None right now.

Trials

  • ARGXargenx
    0Calm

    ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

    Signing up patientsPhase 240 patientsMain results: Oct 2027
  • ARGXargenx
    0Calm

    Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis

    Invite-only sign-upPhase 2/312 patientsMain results: Sep 2029
  • ARGXargenx
    0Calm

    Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis

    Running, no new patientsPhase 2/315 patientsMain results: Mar 2027
  • ARGXargenx
    0Calm

    A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis

    Signing up patientsPhase 2/312 patientsMain results: Sep 2027
  • ARGXargenx
    0Calm

    ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

    Signing up patientsPhase 270 patientsMain results: Mar 7, 2028
  • ARGXargenx
    0Calm

    A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

    Running, no new patientsPhase 3119 patientsMain results: Jun 30, 2025
  • ARGXargenx
    0Calm

    A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

    Running, no new patientsPhase 3141 patientsMain results: Jan 12, 2026
  • ARGXargenx
    0Calm

    Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis

    FinishedPhase 3184 patientsMain results: Dec 31, 2024

Key executives leaving

From the last 12 months of the company's SEC reports.

None found.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

0 sales (0 not pre-planned) · 0 purchases

No insider sales or purchases in the last 6 months.

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

  • None in the last 12 months.

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.